High-dose denosumab (Xgeva®) Associated Medication-Related Osteonecrosis of the Jaws (MRONJ): incidence and clinical characteristics in a retrospective analysis of 1278 patients
Supportive Care in Cancer · 2024-12 · 32 (12)
DOI: 10.1007/s00520-024-08974-6 ↗Kurz gefasst
Fachartikel in der Zeitschrift Supportive Care in Cancer, online erschienen am 05.11.2024. Verfasst von Chiho Moon und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oral and Maxillofacial Surgery, Pusan National University Dental Hospital, Yangsan, Republic of Korea. Hauptthemen laut MEDLINE: Denosumab, Bone Density Conservation Agents. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 27 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: High-dose denosumab (Xgeva®) is increasingly used for treating bone metastasis and various malignant diseases but carries the risk of medication-related osteonecrosis of the jaw (MRONJ). This study aimed to evaluate the incidence, risk factors, and clinical outcomes of MRONJ in patients treated with high-dose denosumab. METHODS: A retrospective review was performed on 1278 patients who received high-dose denosumab at Severance Hospital, Seoul, South Korea, from September 2014 to February 2023. Data on the incidence of MRONJ, patient demographics, primary diseases, and treatment outcomes were analyzed. RESULTS: Among the 1278 patients (average age 64.72 years; 728 males and 550 females) treated, 34 developed MRONJ, with a 2.66% incidence rate. The average age of those with MRONJ was 68.32 years, and they received more Xgeva® injections on average (13.62) compared to the overall cohort. Factors such as age and the frequency of injections were significantly associated with the risk of MRONJ. Notably, the incidence of MRONJ did not significantly differ between those who underwent oral surgery and those with spontaneous MRONJ, especially if oral surgery occurred within 1 month of injection. Surgical interventions have shown higher recovery rates in advanced MRONJ stages. CONCLUSION: This study confirmed a significant MRONJ incidence of 2.66% among high-dose denosumab recipients, highlighting the importance of careful patient selection, monitoring, and education, particularly in older and long-term treatment patients, to mitigate the risk of MRONJ.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oral and Maxillofacial Surgery, Pusan National University Dental Hospital, Yangsan, Republic of Korea.
- Department of Oral and Maxillofacial Surgery, Yonsei University College of Dentistry, Seoul, Republic of Korea.
- Department of Advanced General Dentistry, Yonsei University College of Dentistry, Seoul, Republic of Korea.
- Institute for Innovation in Digital Healthcare, Yonsei University, Seoul, Republic of Korea.
- Department of Oral and Maxillofacial Surgery, Yonsei University College of Dentistry, Seoul, Republic of Korea. JYOMFS@yuhs.ac.
- Institute for Innovation in Digital Healthcare, Yonsei University, Seoul, Republic of Korea. JYOMFS@yuhs.ac.
Zitieren
APA
Moon, C., Kim, H., Park, J. H., Park, W., Kim, H. J., Jung, Y. S., & Kim, J. Y. (2024). High-dose denosumab (Xgeva®) Associated Medication-Related Osteonecrosis of the Jaws (MRONJ): incidence and clinical characteristics in a retrospective analysis of 1278 patients. Supportive Care in Cancer, 32(12). https://doi.org/10.1007/s00520-024-08974-6
Vancouver
Moon C, Kim H, Park JH, Park W, Kim HJ, Jung YS, et al. High-dose denosumab (Xgeva®) Associated Medication-Related Osteonecrosis of the Jaws (MRONJ): incidence and clinical characteristics in a retrospective analysis of 1278 patients. Supportive Care in Cancer. 2024;32(12). doi:10.1007/s00520-024-08974-6
BibTeX
@article{Moon2024,
author = {Moon, Chiho and Kim, Hyounmin and Park, Jin Hoo and Park, Wonse and Kim, Hyung Jun and Jung, Young-Soo and Kim, Jun-Young},
title = {High-dose denosumab (Xgeva®) Associated Medication-Related Osteonecrosis of the Jaws (MRONJ): incidence and clinical characteristics in a retrospective analysis of 1278 patients},
journal = {Supportive Care in Cancer},
year = {2024},
volume = {32},
number = {12},
doi = {10.1007/s00520-024-08974-6}
}
EUVIMED